DK1246814T3 - Forbindelser og fremgangsmåder til modulation af östrogenreceptorer - Google Patents

Forbindelser og fremgangsmåder til modulation af östrogenreceptorer

Info

Publication number
DK1246814T3
DK1246814T3 DK00990966T DK00990966T DK1246814T3 DK 1246814 T3 DK1246814 T3 DK 1246814T3 DK 00990966 T DK00990966 T DK 00990966T DK 00990966 T DK00990966 T DK 00990966T DK 1246814 T3 DK1246814 T3 DK 1246814T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
disclosed
beta
same
Prior art date
Application number
DK00990966T
Other languages
English (en)
Inventor
Shripad S Bhagwat
Jeffrey A Mckie
Sak Khammungkhune
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/492,939 external-priority patent/US6291456B1/en
Priority claimed from US09/611,156 external-priority patent/US6331562B1/en
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of DK1246814T3 publication Critical patent/DK1246814T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00990966T 1999-12-30 2000-12-29 Forbindelser og fremgangsmåder til modulation af östrogenreceptorer DK1246814T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47577699A 1999-12-30 1999-12-30
US09/492,939 US6291456B1 (en) 1998-12-30 2000-01-27 Compounds and methods for modulation of estrogen receptors
US09/611,156 US6331562B1 (en) 1998-12-30 2000-07-06 Compounds and methods for modulation of estrogen receptors
PCT/US2000/035671 WO2001049673A2 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number Publication Date
DK1246814T3 true DK1246814T3 (da) 2005-05-30

Family

ID=27413348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990966T DK1246814T3 (da) 1999-12-30 2000-12-29 Forbindelser og fremgangsmåder til modulation af östrogenreceptorer

Country Status (13)

Country Link
EP (1) EP1246814B1 (da)
JP (1) JP2003519219A (da)
KR (1) KR20020075388A (da)
CN (1) CN1281598C (da)
AT (1) ATE289300T1 (da)
AU (1) AU781282B2 (da)
CA (1) CA2396059A1 (da)
DE (1) DE60018215T2 (da)
DK (1) DK1246814T3 (da)
ES (1) ES2238034T3 (da)
IL (1) IL150463A0 (da)
PT (1) PT1246814E (da)
WO (1) WO2001049673A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
AU2005202072B2 (en) * 2001-11-29 2008-10-23 Gtx, Inc. Prevention and treatment of androgen-deprivation induced conditions
EP1666033B1 (en) * 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
US7098340B2 (en) * 2003-05-14 2006-08-29 Warner Lambert Company Llc Benzyl sulfonamide derivatives
AU2004274445A1 (en) * 2003-09-15 2005-03-31 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CA2595472A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel coumarin derivatives as ion channel openers
ES2436028T3 (es) * 2006-06-23 2013-12-26 Radius Health, Inc. Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
CN106492204A (zh) * 2016-12-27 2017-03-15 郑州郑先医药科技有限公司 一种治疗白内障的药物组合物
CN106727637A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗白内障的西药组合物及其用途
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
AU1367297A (en) * 1996-01-11 1997-08-01 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
JP2002533456A (ja) * 1998-12-30 2002-10-08 シグナル ファーマシューティカルズ, インコーポレイテッド エストロゲン受容体のモジュレートを行うための化合物および方法

Also Published As

Publication number Publication date
IL150463A0 (en) 2002-12-01
ES2238034T3 (es) 2005-08-16
WO2001049673A2 (en) 2001-07-12
CN1437591A (zh) 2003-08-20
EP1246814A2 (en) 2002-10-09
DE60018215T2 (de) 2006-02-09
AU781282B2 (en) 2005-05-12
AU3077101A (en) 2001-07-16
JP2003519219A (ja) 2003-06-17
HK1058521A1 (en) 2004-05-21
CA2396059A1 (en) 2001-07-12
EP1246814B1 (en) 2005-02-16
KR20020075388A (ko) 2002-10-04
WO2001049673A3 (en) 2001-12-06
CN1281598C (zh) 2006-10-25
ATE289300T1 (de) 2005-03-15
PT1246814E (pt) 2005-07-29
DE60018215D1 (de) 2005-03-24

Similar Documents

Publication Publication Date Title
PT1246814E (pt) Compostos e metodos para a modulacao de receptores de estrgenio
DK1140889T3 (da) Forbindelser og metoder til modulation af estrogen-receptorer
WO2000055137A8 (en) Compounds and methods for modulation of estrogen receptors
MY115784A (en) Estrogen agonists/antagonists
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
MX9505249A (es) Agonistas de estrogeno.
CR6478A (es) Moduladores del receptor glucocorticoide
AU2002367060A1 (en) Heterocyclic modulators of nuclear receptors
DK1169417T3 (da) Hydrobehandling ved anvendelse af bulk-gruppe VIII/gruppe VIB katalysatorer
PE20040678A1 (es) Moduladores de los receptores selectivos de estrogenos
EA200970811A1 (ru) Новые производные бензамида в качестве модуляторов фолликулостимулирующего гормона
BR0312024A (pt) Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios
ATE292468T1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
TW200731969A (en) Use of progesterone receptor modulators
DE60233111D1 (de) Glucocorticoid-rezeptoren-modulatoren
DK1272457T3 (da) Forbindelser til modulation af celleproliferation
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
PT1273572E (pt) Piperazinas substituidas com tiofeno uteis no tratamento da hiperplasia prostatica benigna
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
TR200003220T2 (tr) İyi huylu prostat hiperplasianın tedavisinde yararlı olan yeni sübstitüe edilmiş piridino arilpiperazinler
Friedman The Estradiol-Dihydrotestosterone model of prostate cancer
DK1196428T3 (da) 11-beta-aryl-17,17-spirothiolan-substituerede steroider
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
Meyers The role of hormone receptors in estrogen activity is questionable
MY137604A (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith